Brii Bio takes hepatitis B treatment option

hepatitis B

Brii Biosciences Limited, based in China and the U.S., has exercised its option to acquire exclusive development and commercialization rights for VIR-3434 in Greater China as part of its broader collaboration with Vir Biotechnology, Inc. 

VIR-3434, also known as BRII-877, is a broadly neutralizing monoclonal antibody targeting hepatitis B virus (HBV) that is currently in phase 2 development. This is Brii Bio’s second option exercise to a Vir infectious disease program with two remaining options still available to the company.

This move provides additional growth to Brii Bio’s clinical pipeline of therapeutic candidates for HBV. The company said adding another treatments provides more combination options to explore as part of its efforts to develop a functional cure for HBV.

“By exercising our option for VIR-3434 (BRII-877), Brii further solidifies our leading position in developing a functional cure for millions of HBV patients in China,” said Li Yan, chief medical officer of Brii Bio. 

“Recently announced data by Vir showed that BRII-835 (VIR-2218) and BRII-877 (VIR-3434) are additive to each other resulting in a robust reduction of hepatitis B surface antigen (HBsAg), with no clinically significant safety signals for the combination. 

“We are confident that this new asset further strengthens our HBV pipeline by providing more potent and assured reduction of HBsAg in all patients. BRII-877 (VIR-3434) will be integrated into our innovative drug combination strategies that may lead to a higher functional cure rate across all patient groups. 

“Our continued strategic partnership with Vir and the ongoing expansion of our already robust HBV pipeline reinforces our commitment to patients living with HBV as we aim to explore a range of combination treatment options.”

Combining treatments

As part of Brii Bio’s approach to developing a functional cure for HBV by leveraging potential combination treatments, the company said it is currently progressing multiple studies with the BRII-179 (VBI-2601) and BRII-835 (VIR-2218) combination, as well as BRII-179 and/or BRII-835 in combination with other agents. 

Vir is also evaluating VIR-2218 (BRII-835) in a phase 2 study for HBV with selgantolimod (GS-9688), Gilead’s investigational TLR-8 agonist, and nivolumab, an approved PD-1 inhibitor. Several combinations involving BRII-835 (VIR-2218), BRII-877 (VIR-3434) and BRII-179 (VBI-2601) are being investigated in phase 2 studies.

In May 2018, Brii Bio entered into a collaboration, option and license agreement with Vir, under which Brii Bio was granted the option to acquire exclusive rights to certain Vir programs in Greater China. In June 2020, Brii Bio exercised its option to acquire the exclusive rights to further develop and commercialize BRII-835 (VIR-2218) in Greater China.

Under the terms of the agreement, following the exercise of the option for VIR-3434 (BRII-877), Brii Bio will pay an option exercise fee, regulatory and commercial milestone payments, and tiered royalty payments based on net sales with royalty rates from mid-teens to mid-twenties, with such royalty rates or payments subject to certain specified reductions and offsets.

About BRII-877 (VIR-3434)

BRII-877 (VIR-3434) is an investigational subcutaneously administered HBV-neutralizing monoclonal antibody designed to block entry of all 10 genotypes of HBV into hepatocytes and also to reduce the level of virions and subviral particles in the blood. 

BRII-877 (VIR-3434), which incorporates Xencor’s Xtend and other Fc technologies, has been engineered to potentially function as a T cell vaccine against HBV in infected patients, as well as to have an extended half-life.

About hepatitis B

The World Health Organization estimates 296 million people were living with chronic hepatitis B infection in 2019, with 1.5 million new infections each year.

In 2019, hepatitis B resulted in an estimated 820 000 deaths, mostly from cirrhosis and hepatocellular carcinoma (primary liver cancer).

Explore other topics: ChinahepatitisUSAWHO

Newsletter Signup - Under Article / In Page

"*" indicates required fields

Subscribe to our newsletter to get the latest biotech news!

This field is for validation purposes and should be left unchanged.